Concurrently, advanced molecular therapeutics are emerging, including mitophagy inducers (e.g., urolithin A, nicotinamide riboside) to restore mitochondrial quality control (187, 188), gut microbiome engineering to reduce systemic inflammation (189), and innovative RNA therapeutics and gene circuits (e.g., olezarsen, the CHARM system) for long-term management of dyslipidemia (182, 183)
An average relative signal of 0.03 was estimated, comparing glutathionylated peptides to alkylated peptides
Clinical experience suggests good tolerability, with: Mild injection site reactions Occasional digestive changes (particularly with oral administration) Rarely reported headache Important Safety Considerations Both peptides should be prescribed and monitored by qualified medical providers Quality of peptide sourcing matters compounding pharmacies should be licensed and regulated Lab monitoring (particularly IGF-1 for sermorelin) is essential for ongoing safety Contraindications (active malignancies, certain medical conditions) must be evaluated Medical Disclaimer Sermorelin was previously FDA-approved for diagnostic use (Geref Diagnostic) and is currently prescribed off-label through compounding pharmacies
The eight RCTs were published between 2010 and 2021 and conducted in three countries, including Iran ( n = 5) [13, 1618, 35], Korea ( n = 2) [32, 33], and Italy ( n = 1) [34]